Cytek Biosciences

Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cytek Biosciences reports robust earnings, eyes growth through acquisitions

Cytek Biosciences delivered strong financial results in Q4 2022 and full year 2022, driven by revenue growth, strategic partnerships, and acquisitions.
The company's focus on revenue diversification, technological enhancements, and operational efficiencies positions it for continued growth and innovation in 2023.
While facing integration and operational challenges, Cytek remains optimistic about revenue growth, market expansion, and service margin improvements in the coming year.

Cytek Biosciences reports mixed Q1 results, eyes strategic growth

Cytek Biosciences saw mixed Q1 performance with revenue growth from acquisitions but organic revenue decline.
Strategic partnerships and product launches are strengthening Cytek's position in the market.
Challenges in revenue growth and increased expenses highlight the need for operational efficiency.
Despite financial setbacks, Cytek remains optimistic about future growth opportunities and market leadership.

Cytek Biosciences reports strong Q2 earnings, eyes growth opportunities

Cytek Biosciences delivered a robust performance in Q2 2023, marked by strong revenue growth and operational efficiency despite increased expenses.
The company's strategic focus on driving growth through acquisitions, technology advancements, and market opportunities bodes well for future expansion.
While challenges in managing expenses persist, Cytek's solid financial position and confidence in addressing market needs position it for sustained growth.
With a clear roadmap for growth and a talented team, Cytek remains poised to capitalize on opportunities and enhance shareholder value.

Cytek Biosciences reports solid Q3 growth and eyes global expansion

Cytek Biosciences delivered strong Q3 results with revenue growth and strategic focus on key pillars.
Despite challenges in sales cycles and order delays, the company remains innovative and responsive in the market.
Opportunities in new product launches, bioinformatics, and clinical markets provide avenues for future growth.
Cytek's performance reflects resilience amidst industry challenges and a commitment to driving innovation and expansion.

Cytek Biosciences reports robust Q4 earnings, eyes growth opportunities

Cytek Biosciences delivered strong financial results in Q4 2023, driven by revenue growth and operational efficiency, with a focus on profitability and innovation.
The company faces challenges in managing expenses, stabilizing revenue in key markets, and balancing new product contributions with cost control measures.
Opportunities lie in capitalizing on revenue outlook, expanding in the biotech segment, leveraging regional growth, and diversifying revenue streams.
Strategic planning and execution will be crucial for Cytek Biosciences to navigate challenges and maximize opportunities for sustainable growth and market leadership.

Cytek Biosciences reports strong Q1 growth amidst global market expansion

Cytek Biosciences' Q1 2024 performance reflects solid revenue growth and market expansion efforts.
While facing challenges in certain regions, the company is leveraging opportunities in product innovation and global demand.
Maintaining financial discipline and focusing on operational efficiency will be key to achieving profitability and sustained growth.

Cytek Biosciences reports Q2 revenue growth, eyes global expansion

Cytek Biosciences showed mixed performance in Q2 2024 with revenue growth in EMEA and APAC but a decline in the U.S., particularly in academic and government sectors.
The company's focus on key growth pillars and new capabilities like the ESP module, along with strategic initiatives like Cytek Cloud, positions it for future growth.
While facing challenges in the U.S. market, Cytek Biosciences aims to drive sustainable growth and profitability through cost control and revenue enhancement strategies.

Cytek Biosciences reports strong Q3 earnings, eyes global expansion

Cytek Biosciences demonstrated solid financial performance in Q3 2024, driven by revenue growth and effective expense management.
The company's strategic focus on key pillars and expanding user base positions it well for future success and market leadership.
While facing challenges in balancing investments and income, Cytek has opportunities to capitalize on global growth and market trends.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.

Corcept Therapeutics

The most oversold stocks in the healthcare sector presents an opportunity to buy into undervalued companies.

5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More - Corcept Therapeutics (NASDAQ:CORT), Cytek Biosciences (NASDAQ:CTKB)

FREMONT, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York, NY.

Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference

New Digital Ecosystem Supports Full Spectrum Flow Cytometry Research – from Panel Design to Data Acquisition New Digital Ecosystem Supports Full Spectrum Flow Cytometry Research – from Panel Design to Data Acquisition

Cytek® Biosciences Introduces Cytek Cloud

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Paul Goodson - Head, IR Wenbin Jiang - President, CEO and Chairman Patrik Jeanmonod - CFO Conference Call Participants Tejas Savant - Morgan Stanley Matthew Sykes - Goldman Sachs David Westenberg - Piper Sandler Operator Welcome to Cytek's Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Cytek Biosciences, Inc. (CTKB) Q3 2022 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 100% and 6.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates

Third quarter revenue grew 18% compared to prior year quarter

Cytek Biosciences Reports Third Quarter 2022 Financial Results

Experienced Biotech, Pharmaceutical Industry Leader to Guide Operations Growth and Scalability

Cytek® Biosciences Names Chris Williams Chief Operating Officer

FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 9th, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report Third Quarter 2022 Financial Results on November 9, 2022

FREMONT, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 31st Annual Credit Suisse Healthcare Conference in Rancho Palos Verdes, CA.

Cytek to Participate in the 31st Annual Credit Suisse Healthcare Conference

FREMONT, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 20th Annual Morgan Stanley Global Healthcare Conference in New York, NY.

Cytek to Participate in the 20th Annual Morgan Stanley Global Healthcare Conference

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Paul Goodson - Head, IR Wenbin Jiang - President, CEO and Chairman Patrik Jeanmonod - CFO Conference Call Participants Max Masucci - Cowen & Company Matt Sykes - Goldman Sachs David Westenberg - Piper Sandler Tejas Savant - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Cytek Biosciences' Second Quarter 2022 Earnings Conference Call.

Cytek Biosciences, Inc. (CTKB) CEO Wenbin Jiang on Q2 2022 Results Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 50% and 2.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates

Second quarter revenue grew 32% compared to prior year Second quarter revenue grew 32% compared to prior year

Cytek Biosciences Reports Second Quarter 2022 Financial Results

10X Genomics

Cytek and 10x Genomics both offer single cell visualization tools, a growing and important field in modern medicine. However, each company sees huge differences in popularity, financial performance, and valuation, leading to a significant difference in outlook.

Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments

FREMONT, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, MA.

Cytek to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

FREMONT, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 10th, 2022. The company's management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report Second Quarter 2022 Financial Results on August 10, 2022

FREMONT, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) announced today that it will host its inaugural Analyst and Investor Day on Wednesday June 22, with presentations beginning at 9:00 a.m. ET.

Cytek Biosciences to Host Inaugural Analyst and Investor Day

Company Moves to Make Total Cell Analysis Solutions Available for Clinical Applications in the European Market Company Moves to Make Total Cell Analysis Solutions Available for Clinical Applications in the European Market

Cytek® Biosciences Receives CE Marking for Series of cFluor® Reagents, TBNK Kit

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2022 Earnings Conference Call May 11, 2022 5:00 PM ET Company Participants Paul Goodson - Head, IR Wenbin Jiang - President, CEO & Chairman Patrik Jeanmonod - CFO Conference Call Participants Max Masucci - Cowen and Company Matthew Sykes - Goldman Sachs Group David Westenberg - Piper Sandler & Co. Tejas Savant - Morgan Stanley Operator Thank you for standing by, and welcome to the Cytek Biosciences First Quarter 2022 Earnings Conference Call. [Operator Instructions].

Cytek Biosciences, Inc. (CTKB) CEO Wenbin Jiang on Q1 2022 Results - Earnings Call Transcript

First quarter revenue grew 44% compared to prior year First quarter revenue grew 44% compared to prior year

Cytek Biosciences Reports First Quarter 2022 Financial Results

FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11th, 2022. The company's management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022

Industry Seasoned Executive Joins Cytek Industry Seasoned Executive Joins Cytek

Cytek Biosciences Appoints Todd Garland Chief Commercial Officer

Clearwater Analytics Holdings

Occidental Petroleum

Procore Technologies

Although US stock futures traded lower this morning on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain.

Executives Buy More Than $1B Of 4 Stocks

Cytek Biosciences, Inc.'s (CTKB) CEO Wenbin Jiang on Q4 2021 Results - Earnings Call Transcript

2021 Revenue Increased 38% Compared to Prior Year

News for Cytek Biosciences Stock (CTKB)